🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI

Found 19 matching trials

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

PHASE3

Efficacy and tolerability of the fixed combination Beclomethasone Dipropion...

Status

Completed

Location

Multiple Locations

Start Date

2004-08

Trial ID

NCT00862264

Treatments Being Tested

Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI

Study in Adult Patients With Moderate to Severe Asthma

PHASE3

This study assessed the influence of pink vs. white pressurized metered-dos...

Status

Completed

Location

Chiesi Clinical Trial Site 38011

Start Date

2022-02-24

Trial ID

NCT04886999

Treatments Being Tested

Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A)Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)

Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children

PHASE2

The purpose of this clinical study is to compare the improvement in breathi...

Status

Completed

Location

Poradnia Alergologiczna

Start Date

2011-12

Trial ID

NCT01584492

Treatments Being Tested

beclomethasone+formoterol 50/6 (1 inhalation)CHF 1535 50/6 (2 inhalations)CHF 1535 50/6 (4 inhalations)Formoterol + Beclomethasone dipropionate Placebo (6 inhalations)

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

PHASE4

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3...

Status

Completed

Location

PAREXEL International GmbH Early Phase Clinical Unit Berlin

Start Date

2021-10-28

Trial ID

NCT05097014

Treatments Being Tested

CHF5993 CHF1535 Matched placebo

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

PHASE3

Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose...

Status

Completed

Location

Chiesi Clinical Trial Site 276814

Start Date

2016-02-17

Trial ID

NCT02676076

Treatments Being Tested

CHF 5993 100/6/12.5 CHF 1535 100/6 µg

A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.

PHASE2

The clinical trial is designed to evaluate the non-inferiority of CHF1535 1...

Status

Completed

Location

University of Dundee

Start Date

2017-02-28

Trial ID

NCT03108534

Treatments Being Tested

CHF1535 NEXThaler CHF1535 pMDI Placebo

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

PHASE3

The aim of this study was to compare the efficacy and tolerability of the f...

Status

Completed

Location

Ambulance For Paediatric and Pulmonology

Start Date

2004-09

Trial ID

NCT00413387

Treatments Being Tested

beclomethasone dipropionate plus formoterol fumarate combination budesonide plus formoterol combination

Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI

PHASE2

The aim of this clinical study is to compare the lung exposure of the conte...

Status

Completed

Location

Medicines Evaluation Unit Ltd

Start Date

2011-05

Trial ID

NCT01349257

Treatments Being Tested

BDP/Formoterol

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

PHASE3

Primary Objective To demonstrate that CHF 1535 pMDI is non-inferior to Sym...

Status

Completed

Location

Site 15604 - Anhui Provincial Hospital

Start Date

2018-07-30

Trial ID

NCT03888131

Treatments Being Tested

CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients

PHASE2

This clinical pharmacology want to investigate the systemic availability of...

Status

Completed

Location

Uniwersytecki Szpital Kliniczny nr 1

Start Date

2012-02

Trial ID

NCT01803087

Treatments Being Tested

Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1 CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)CHF 1535 100/6 pMDI (Foster®) (CTR)

Previous Next